Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Feb. 27, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | ARCT | ||
| Entity Registrant Name | ARCTURUS THERAPEUTICS HOLDINGS INC. | ||
| Entity Central Index Key | 0001768224 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Small Business | false | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | true | ||
| Document Financial Statement Error Correction | false | ||
| Entity Shell Company | false | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Interactive Data Current | Yes | ||
| Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
| Security Exchange Name | NASDAQ | ||
| Entity File Number | 001-38942 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 32-0595345 | ||
| Entity Address, Address Line One | 10285 Science Center Drive | ||
| Entity Address, City or Town | San Diego | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 92121 | ||
| City Area Code | 858 | ||
| Local Phone Number | 900-2660 | ||
| Entity Common Stock, Shares Outstanding | 28,423,069 | ||
| Entity Public Float | $ 323.5 | ||
| Document Transition Report | false | ||
| Document Annual Report | true | ||
| Documents incorporated by reference | Certain portions of the registrant’s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K. |
||
| Auditor Firm ID | 34 | ||
| Auditor Name | Deloitte & Touche LLP | ||
| Auditor Location | San Diego, California | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Arcturus Therapeutics Holdings, Inc. and subsidiaries (the “Company”) as of December 31, 2025, and 2024, the related consolidated statements of operations, comprehensive loss, stockholder’s equity, and cash flows, for each of the two years in the period ended December 31, 2025 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 3, 2026, expressed an unqualified opinion on the Company’s internal control over financial reporting. |